CELZ-201-DDT for Chronic Lower Back Pain
This study is testing CELZ-201-DDT, given as injections into the lower back muscles, for people with chronic lower back pain caused by degenerative disc disease. Researchers want to see how safe and well CELZ-201-DDT works compared to a placebo (an inactive substance). You might be able to join if you are 18-80 years old and have tried at least two standard treatments for your back pain, like exercise or pain medications, without success. The main goal is to check the safety of CELZ-201-DDT at different doses over 6 months.
- Study design
- This is a randomized, double-blinded, placebo-controlled study with about 45 participants. It is designed to test different doses of CELZ-201-DDT.
- What's involved
- Participants will receive a total of six injections into their lower back muscles, three on each side, guided by ultrasound. The study will evaluate safety for 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will evaluate safety for 6 months after the injections.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06053242
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Active, Not Recruiting
PHASE1Ages 18–80InterventionalTreatmentCreative Medical Technology Holdings Inc
~45 participants
Updated 2026-08-21 on ClinicalTrials.gov
What's tested:CELZ-201-DDTPlacebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.
Measured over 6 months
Conditions
Where it's being run
1 sites across 1 statesFlorida1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Ability of participant to understand and the willingness to sign a written informed consent document.
Between 18-80 years of age and may be of either gender or any race.
Subjects must have failed at least two standard of care (SOC) therapies before being enrolled in the study: 1) exercise/physical therapy; 2) oral analgesic including nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; 3) skeletal muscle relaxants. Subjects must have tried each SOC therapy for at least 3 months before failure is determined.
Patients must have failed the SOC therapies within 12 months of enrollment in the clinical trial.
Proof for one of the following tests already performed in the clinical care of the patient for lower back pain: 1) MRI scan demonstrating at least one disc level with grade II or greater disc degeneration using the Pfirrmann grading system; 2) Oswestry Disability Index for Back Pain score of 21-80%; 3) Visual Analogue Scale for pain of \>5 on a scale of 0-10.
Female subjects must not be breast feeding and must have no intention to become pregnant during the study, and she is using contraceptive drugs or devices.
Any male subject must agree to use contraceptives and not donate sperm during the study.
Subjects may be on stable opioids, narcotics, or muscle relaxants for ≥30 days before screening.
Exclusion
History of cancer in the last five years.
Spinal infections and spinal tumors.
Renal insufficiency requiring dialysis or an eGFR of less than 60 mL/min/1.73m2.
ALT, AST greater than 2 times or Total Bilirubin 1.5 times the upper limit of the normal range.
Positive pregnancy test.
History of blood cell diseases.
Uncontrolled diabetes mellitus - HgA1c \>8%.
Uncontrolled hypertension defined as a systolic blood pressure of \>140 mmHg or diastolic blood pressure of \>90 mmHg at the time of screening. If subjects have their hypertension appropriately treated, then they would be eligible to enroll.
Patients known to have any active infection, including infection of the injection site(s), and/or any active systemic or local infection.
Patients on chronic immunosuppressive transplant therapy. Patients receiving \<5 mg of Prednisone daily may be included.
Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.
Recent smoking history or substance abuse (within six weeks).
Heavy alcohol use (greater than 14 drinks per week for men or 7 drinks per week for women per NIAAA)
Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving study treatment.
Any patient who has received gene therapy in the past.
Subjects with an average baseline MED \>90 mg/day during the screening period are excluded. The average will be calculated over a 7-day time period.
Body Mass Index (BMI) \> 40 kg/m2.
What this trial measures
- Evaluate safety of CELZ-201-DDT administered as intramuscular injections in subjects experiencing chronic lower back pain at a low, medium, or high dose.6 months
The primary outcome will be evaluated by the incidence of grade 3 or 4 or serious adverse events in all dosing cohorts at 6 months.